Reach
Get to the tumor.
Programmable durability
for solid-tumor cell therapy.
Ready when patients need them.
Built to endure when tumors fight back.
CAR-T therapies use engineered immune cells to recognize and attack cancer. We design those cells to resist the signals tumors use to shut them down.
The durability gap
In recurrent glioblastoma, CAR-T can shrink tumors. Control often does not last.
Published GBM CAR-T example Not KGEN-001
Before CAR-T
After CAR-T
8 of 13 Patients with measurable tumors showed shrinkage on imagingRadiographic regression 1.9 months Median progression-free survivalTime until disease progression or death
WHAT DURABLE CONTROL REQUIRES
A response is only the beginning.
A complete product must do all four.
ReadyAvailable when treatment is needed.
Recognize
See enough of the tumor to limit escape.
Defining advance
Resist
Keep working when the tumor fights back.
Our approach to resistance
Noise cancellation for cell therapy.
We use multiplex gene editing to help CAR-T cells resist several suppressive routes at once.
The tumor keeps sending the signals. We change which ones the cell can hear.
A lead program. A system for what comes next.
Backed by investors. Supported by disease foundations.
Investor backing
Disease foundation support
